Park Pil-Gu, Lee Seok-Yong, Youn Hyewon, Hong Kee-Jong
Department of Life Science, Gachon University, Seongnam 13120, Republic of Korea.
Department of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Int J Mol Sci. 2025 May 20;26(10):4893. doi: 10.3390/ijms26104893.
Emerging infectious diseases (EIDs) are one of the greatest threats to human health today, thus requiring an urgent response. Vaccines are one of the most effective means of preventing the spread of infectious diseases, and their usefulness in responding to EIDs has been clearly proven through the process of overcoming the global COVID-19 pandemic. As the characteristics of various vaccine formulations differ, it is necessary to apply the most appropriate one according to the EID response strategy. In this review, we first consider which vaccine formulation is the most suitable for EID vaccines by comparing the pros and cons of different vaccine formulations, and then we discuss the utility of mRNA vaccine formulations, which are considered the most promising for EID vaccines.
新发传染病（EIDs）是当今人类健康面临的最大威胁之一，因此需要紧急应对。疫苗是预防传染病传播的最有效手段之一，通过战胜全球新冠疫情的过程，疫苗在应对新发传染病方面的效用已得到明确证明。由于各种疫苗制剂的特性不同，有必要根据新发传染病应对策略应用最合适的疫苗制剂。在本综述中，我们首先通过比较不同疫苗制剂的优缺点，考量哪种疫苗制剂最适合用于新发传染病疫苗，然后讨论被认为在新发传染病疫苗方面最具潜力的mRNA疫苗制剂的效用。
Int J Mol Sci. 2025-5-20
Nat Med. 2021-4
Nat Rev Immunol. 2021-12
Semin Immunol. 2020-8
Curr Opin Immunol. 2020-8
Biomolecules. 2025-3-1
Clin Immunol. 2025-2
Vaccines (Basel). 2024-10-8
Hum Vaccin Immunother. 2024-12-31
J Acquir Immune Defic Syndr. 2024-8-1
J Mol Biol. 2023-12-1
Zotero 插件